First previewed in the company's May roadmap, the new withZeta.ai module now enters early access with leading bioinformatics teams and Lantern collaborators — autonomously designing experiments, building rigorous cohorts from 615,000+ curated cancer samples, and delivering publication-ready multi-omic analysis in minutes
A new class of research agent. ZetaOmics™ is an autonomous "Computational Biologist" that goes beyond automating software — it reasons about experimental design, prevents pitfalls that produce false discoveries, and makes statistically rigorous decisions on its own, encoding the judgment of a tenured bioinformatician so that scientific rigor is the default across rare and common cancers alike.
Intelligent discovery, analysis, and cohort-building at scale. Through direct access to more than 615,000 curated cancer samples across eleven data sources, ZetaOmics resolves fragmented data and vocabularies autonomously and builds meaningful, analysis-ready cohorts from natural-language questions — turning weeks of manual data wrangling into minutes.
Publication quality output that accelerates insights. From differential expression and pathway enrichment to survival modeling, drug-response and protein-level validation, ZetaOmics delivers auditable, publication-quality results and figures inside a single conversational workflow — changing and accelerating how bioinformatics and computational biology get done.
DALLAS, July 08, 2026--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous "Computational Biologist" persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been underserved by dedicated computational resources and meaningful bioinformatics.
First introduced as part of the withZeta.ai development roadmap the Company unveiled on May 7, 2026, ZetaOmics now moves from roadmap to reality. It is being made available initially through an early-access program for a select group of leading academic and industry bioinformatics teams and Lantern Pharma collaborators, whose real-world use will guide refinement ahead of broader commercial availability. This phased rollout is designed to validate the module against the most demanding research workflows while establishing the reference relationships that seed a larger subscriber and partnership base.